At the news
? MIXEDIMPACT 6/10 8-K filed Mar 5, 2026 at 07:41 ET
Silence Therapeutics reported a significant year-over-year decline in revenue and increased net loss, driven by the conclusion of prior collaborations. However, the company highlighted positive clinical progress, including accelerated topline results for its divesiran trial in polycythemia vera expected in Q3 2026, and promising preclinical data for new siRNA programs. The cash position of $85.1 million provides runway for ongoing development.
- Revenue dropped 98.7% YoY to $0.6 million due to conclusion of Hansoh collaboration and reduced AstraZeneca revenue
- Net loss increased 95.5% YoY to $88.6 million
- Cash position of $85.1 million as of December 31, 2025
- Topline results for Phase 2 SANRECO trial of divesiran in polycythemia vera expected in Q3 2026 (accelerated from H2 2026)
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access